Mometasone furoate: An effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma

International Journal of Clinical Practice

Volumn 63, Issue 5, 2009, Pages 806-819

  Bousquet, J ^a  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCOCORTICOID RECEPTOR; INDACATEROL; MOMETASONE FUROATE; PLACEBO;

ABDOMINAL PAIN; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BACKACHE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; DYSMENORRHEA; DYSPEPSIA; EVENING DOSAGE; FORCED EXPIRATORY VOLUME; GROUPS BY AGE; HEADACHE; HUMAN; LUNG FUNCTION; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; MORNING DOSAGE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PHARYNGITIS; POWDER INHALER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFLAMMATION; SINUSITIS; THRUSH; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; HUMANS; MIDDLE AGED; PREGNADIENEDIOLS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64149120682     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02003.x     Document Type: Article

References (88)

1. Bousquet J, Khaltaev N. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases. A Comprehensive Approach. Global Alliance Against Chronic Respiratory Diseases. Geneva : World Health Organization, 2007.
2. Ait-Khaled N, Odhiambo J, Pearce N et al. Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: the International Study of Asthma and Allergies in Childhood Phase III. Allergy 2007 62 : 247 58.
3. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004 59 : 469 78.
4. Dusser D, Montani D, Chanez P et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007 62 : 591 604.
5. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008 31 : 143 78.
6. Busse WW, Lemanske RF Jr. Expert Panel Report 3: moving forward to improve asthma care. J Allergy Clin Immunol 2007 120 : 1012 4.
7. Bousquet J, Clark TJ, Hurd S et al. GINA guidelines on asthma and beyond. Allergy 2007 62 : 102 12.
8. National Heart, Lung, and Blood Institute-National Asthma Education and Prevention Program (NHLBI-NAEPP 2007). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 07-4051. Bethesda, MD : U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 2007.
9. Global Strategy for Asthma Management and Prevention (Updated 2008), Global Initiative for Asthma (GINA). http://www.ginasthma.org (accessed 1 November 2008).
10. Ait-Khaled N, Enarson DA, Bissell K, Billo NE. Access to inhaled corticosteroids is key to improving quality of care for asthma in developing countries. Allergy 2007 62 : 230 6.
11. Bateman ED, Jithoo A. Asthma and allergy - a global perspective. Allergy 2007 62 : 213 5.
12. Canonica GW, Baena-Cagnani CE, Blaiss MS, Dahl R, Kaliner MA, Valovirta EJ. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings. Allergy 2007 62 : 668 74.
13. Dockrell M, Partridge MR, Valovirta E. The limitations of severe asthma: the results of a European survey. Allergy 2007 62 : 134 41.
14. Humbert M, Holgate S, Boulet LP, Bousquet J. Asthma control or severity: that is the question. Allergy 2007 62 : 95 101.
15. Schering-Plough Asmanex® Twisthaler® 200 and 400 g (mometasone furoate inhalation powder); UK prescribing information [online]. http://emc.medicines.org.uk/emc/industry/default.asp?page=displaydoc. asp&documentid=11551 (accessed July 2008).
16. Schering-Plough Asmanex® Twisthaler® 220 g (mometasone furoate inhalation powder); US prescribing information [online]. http://www.spfiles.com/ piasmanex.pdf (accessed July 2008).
17. Chervinsky P, Nelson HS, Bernstein DI, Berkowitz RA, Siegel SC. Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. Int J Clin Pract 2002 56 : 419 25.
18. Karpel JP, Nayak A, Lumry W et al. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respir Med 2007 101 : 628 37.
19. Urbach V, Verriere V, Grumbach Y, Bousquet J, Harvey BJ. Rapid anti-secretory effects of glucocorticoids in human airway epithelium. Steroids 2006 71 : 323 8.
20. Högger P. Current concepts for optimizing the therapeutic index of glucocorticoid receptor ligands for oral and inhalative use: basic considerations and clinical reality. Curr Med Chem Anti-Inflamm Anti-Allergy Agents 2003 2 : 395 408.
21. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998 48 : 956 60.
22. Valotis A, Neukam K, Elert O, Hogger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 2004 93 : 1337 50.
23. Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K. Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol 1993 44 : 141 5.
24. Atsuta J, Plitt J, Bochner BS, Schleimer RP. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol 1999 20 : 643 50.
25. Crocker IC, Church MK, Newton S, Townley RG. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann Allergy Asthma Immunol 1998 80 : 509 16.
26. Chapman RW, Sehring SJ, Garlisi CG et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittelforschung 1998 48 : 384 91.
27. Munthe-Kaas MC, Gerritsen J, Carlsen KH et al. Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes. Allergy 2007 62 : 429 36.
28. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001 344 : 350 62.
29. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodelling. Am J Respir Crit Care Med 2000 161 : 1720 45.
30. Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci 2002 71 : 1523 34.
31. Zhang X, Moilanen E, Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol 2000 406 : 325 32.
32. Inman MD, Watson RM, Rerecich T et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001 164 : 569 74.
33. Sabatini F, Silvestri M, Sale R et al. Concentration-dependent effects of mometasone furoate and dexamethasone on foetal lung fibroblast functions involved in airway inflammation and remodeling. Pulm Pharmacol Ther 2003 16 : 287 97.
34. Nayak AS, Banov C, Corren J et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000 84 : 417 24.
35. Kemp JP, Berkowitz RB, Miller SD, Murray JJ, Nolop K, Harrison JE. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000 106 : 485 92.
36. Bensch GW, Prenner B, Berkowitz R, Galant S, Ramsdell J, Lutsky B. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006 96 : 533 40.
37. Bernstein DI, Berkowitz RB, Chervinsky P et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999 93 : 603 12.
38. Karpel JP, Busse WW, Noonan MJ, Monahan ME, Lutsky B, Staudinger H. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005 39 : 1977 83.
39. D'Urzo A, Karpel JP, Busse WW et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005 21 : 1281 9.
40. Noonan M, Karpel JP, Bensch GW et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001 86 : 36 43.
41. Nathan RA, Nayak AS, Graft DF et al. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann Allergy Asthma Immunol 2001 86 : 203 10.
42. Corren J, Berkowitz R, Murray JJ, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003 57 : 567 72.
43. Fish JE, Karpel JP, Craig TJ et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000 106 : 852 60.
44. Bousquet J, D'Urzo A, Hebert J et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000 16 : 808 16.
45. Wardlaw A, Larivee P, Eller J, Cockcroft DW, Ghaly L, Harris AG. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004 93 : 49 55.
46. O'Connor B, Bonnaud G, Haahtela T et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001 86 : 397 404.
47. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002 24 : 1 20.
48. Aburuz S, Gamble J, Heaney LG. Assessment of impairment in health-related quality of life in patients with difficult asthma: psychometric performance of the Asthma Quality of Life Questionnaire. Respirology 2007 12 : 227 33.
49. Bateman ED, Bousquet J, Keech ML, Busse WW, Clark TJ, Pedersen SE. The correlation between asthma control and health status: the GOAL study. Eur Respir J 2007 29 : 56 63.
50. Carranza-Rosenzweig JR, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med 2004 98 : 1157 65.
51. Schmier J, Leidy NK, Gower R. Reduction in oral corticosteroid use with mometasone furoate dry powder inhaler improves health-related quality of life in patients with severe persistent asthma. J Asthma 2003 40 : 383 93.
52. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992 30 : 473 83.
53. Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement quality of life in adults with asthma. J Clin Epidemiol 1992 45 : 461 72.
54. Nayak AS, Lampl KL, Segall N et al. Long-Term use of Once-Daily Mometasone Furoate is Effective and Well Tolerated in Patients With Mild to Moderate Persistent Asthma. New Orleans, LA : 57th annual meeting of the American Academy of Allergy, Asthma and Immunology; 16-21 March 2001.
55. Murray J, Busse W, Dockhorn R et al. Long-term safety of mometasone furoate (MF) administered by dry powder inhaler (DPI) in patients with moderate persistent asthma. Eur Respir J 2000 16 : 280s 1s.
56. Affrime MB, Cuss F, Padhi D et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000 40 : 1227 36.
57. Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004 170 : 960 6.
58. Wales D, Makker H, Kane J, McDowell P, O'Driscoll BR. Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers. Chest 1999 115 : 1278 84.
59. Whelan GJ, Blumer JL, Martin RJ, Szefler SJ. Asthma Clinical Research Network and the Pediatric Pharmacology Research Unit Network. Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration. J Allergy Clin Immunol 2005 116 : 525 30.
60. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997 91 (Suppl. A 22 8.
61. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982 122 (Suppl. 86 95.
62. Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005 128 : 70 7.
63. Affrime MB. Mometasone furoate levels. Chest 2001 120 : 1035.
64. Affrime MB, Kosoglou T, Thonoor CM, Flannery BE, Herron JM. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest 2000 118 : 1538 46.
65. Leone FT, Fish JE, Szefler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American college of chest physicians, American academy of allergy, asthma, and immunology, and American college of allergy, asthma, and immunology. Chest 2003 124 : 2329 40.
66. Berger WE, Milgrom H, Chervinsky P et al. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 2006 97 : 672 80.
67. Meltzer EO, Baena-Cagnani CE, Chervinsky P, Stewart GE, Bronsky EA, Lutsky BN. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Pediatric Asthma Allergy Immunol 2007 20 : 67 81.
68. Pauwels RA, Pedersen S, Busse WW et al., START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003 361 : 1071 6.
69. Skoner D, Dunn M, Lee T. Effects of mometasone furoate dry powder inhaler on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma (Abstract). Am J Respir Crit Care Med 2003 167 : A272.
70. Lemanske R, Lockey R, Murphy K. Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma (Abstract). Eur Respir J 2004 24 : S378.
71. Pickering H, Pitcairn GR, Hirst PH et al. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler. Clin Ther 2000 22 : 1483 93.
72. Hansen RA, Gartlehner G, Lohr KN, Carson S, Carey T. Drug class review on inhaled corticosteroids. Final Report 2006. http://www.ohsu.edu/ drugeffectiveness/reports/final.cfm (accessed 1 November 2008).
73. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998 157 : S153.
74. Rohatagi S, Appajosyula S, Derendorf H et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic-pharmacodynamic perspective. J Clin Pharmacol 2004 44 : 37 47.
75. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J 1993 6 : 877 85.
76. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999 159 : 941 55.
77. Lee DK, Fardon TC, Bates CE, Haggart K, McFarlane LC, Lipworth BJ. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005 127 : 851 60.
78. Lipworth BJ, Kaliner MA, LaForce CF et al. Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005 94 : 465 72.
79. Mortimer KJ, Harrison TW, Tang Y et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol 2006 62 : 412 9.
80. Tayab ZR, Fardon TC, Lee DK et al. Pharmacokinetic-pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol 2007 64 : 698 705.
81. Abdullah AK, Khan S. Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis. Ann Allergy Asthma Immunol 2008 101 : 74 81.
82. Dolovich MB, Ahrens RC, Hess DR et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians-American College of Asthma, Allergy, and Immunology. Chest 2005 127 : 335 71.
83. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002 96 : 293 304.
84. Yang TT, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med. 2001 14 : 487 94.
85. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005 50 : 367 82.
86. Wyss D, Bonneau O, Trifilieff A. Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation. Br J Pharmacol 2007 152 : 83 90.
87. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001 51 : 400 9.
88. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001 61 : 1325 50.